Piramal Pharma Ltd (PIRM)

Currency in INR
165.95
+2.64(+1.62%)
Closed·
PIRM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
159.00167.88
52 wk Range
148.31240.95
Key Statistics
Bid/Ask
166.00 / 166.05
Prev. Close
163.31
Open
162.5
Day's Range
159-167.88
52 wk Range
148.31-240.95
Volume
4.65M
Average Volume (3m)
3.21M
1-Year Change
-17.2567%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PIRM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
204.60
Upside
+23.29%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to drop this year

Piramal Pharma Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Piramal Pharma Ltd Company Profile

Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, injectable pain and anesthesia drugs, and other generic and specialty products; and analgesics, skin care, vitamin/mineral supplement, kids’ wellness, digestives, women’s health, and hygiene, as well as adult incontinence. The company was incorporated in 2020 and is based in Mumbai, India.

Employees
5476
Market
India

Compare PIRM to Peers and Sector

Metrics to compare
PIRM
Peers
Sector
Relationship
P/E Ratio
−135.1x34.5x−0.5x
PEG Ratio
0.261.650.00
Price/Book
2.7x5.2x2.6x
Price / LTM Sales
2.5x4.8x3.3x
Upside (Analyst Target)
23.5%10.6%47.0%
Fair Value Upside
Unlock3.6%6.1%Unlock

Analyst Ratings

9 Buy
0 Hold
1 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 204.60
(+23.29% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Goldman Sachs
Buy200.00+20.52%225.00MaintainJan 30, 2026
Jefferies
Buy210.00+26.54%235.00MaintainJan 09, 2026
Axis Capital Limited
Buy220.00+32.57%230.00MaintainNov 07, 2025
Kotak
Buy310.00+86.80%325.00MaintainNov 07, 2025
Kotak
Buy325.00+95.84%305.00MaintainOct 24, 2025

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -1.24%
Dividend Yield
0.08%
Industry Median 0.78%
Annualized payout
0.14
Paid annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Jan 28, 2026
EPS / Forecast
-0.70 / 0.05
Revenue / Forecast
21.40B / 22.33B
EPS Revisions
Last 90 days

PIRM Income Statement

People Also Watch

836.05
PNBH
-1.97%
916.75
FOHE
-1.27%
2,340.60
MCEI
-4.15%
106.38
INWN
-2.69%
1,010.60
LAUL
-0.79%

FAQ

What Is the Piramal Pharma (PIRM) Stock Price Today?

The Piramal Pharma stock price today is 165.95

What Stock Exchange Does Piramal Pharma Trade On?

Piramal Pharma is listed and trades on the India National Stock Exchange.

What Is the Stock Symbol for Piramal Pharma?

The stock symbol for Piramal Pharma is "PIRM."

Does Piramal Pharma Pay Dividends? What’s The Current Dividend Yield?

The Piramal Pharma dividend yield is 0.08%.

What Is the Piramal Pharma Market Cap?

As of today, Piramal Pharma market cap is 220.36B.

What Is Piramal Pharma's Earnings Per Share (TTM)?

The Piramal Pharma EPS (TTM) is -1.24.

When Is the Next Piramal Pharma Earnings Date?

Piramal Pharma will release its next earnings report on May 27, 2026.

From a Technical Analysis Perspective, Is PIRM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Piramal Pharma Stock Split?

Piramal Pharma has split 0 times.

How Many Employees Does Piramal Pharma Have?

Piramal Pharma has 5476 employees.

What is the current trading status of Piramal Pharma (PIRM)?

As of Feb 14, 2026, Piramal Pharma (PIRM) is trading at a price of 165.95, with a previous close of 163.31. The stock has fluctuated within a day range of 159.00 to 167.88, while its 52-week range spans from 148.31 to 240.95.

What Is Piramal Pharma (PIRM) Price Target According to Analysts?

The average 12-month price target for Piramal Pharma is INR204.60, with a high estimate of INR285 and a low estimate of INR160. 9 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Strong Buy. The stock has an +23.29% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.